CR
CorMedix Inc.
CRMD · NASDAQ
$7.72 +0.46% (+$0.04)
1M -6.20%
Market Cap $611.1M
P/E Ratio 3.27x
Div. Yield -
ROE 44.64%
Bulios Fair Price
$6.48
16.1% downside
Current Price
$7.72
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CRMD is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
100 /100
Cheap P/E 3.27x
EV/EBITDA 2.00x
P/S 1.32x
Growth
100 /100
Growing Rev. growth 1,582.83%
Book val. growth 94.53%
EPS growth N/A
Profitability
100 /100
Strong Gross margin 82.78%
Net margin 40.49%
Op. margin 46.95%
Quality
91 /100
Excellent ROIC 27.87%
ROE 44.64%
ROA 20.70%
Debt
100 /100
Low Debt/Equity 0.31x
Current ratio 2.56x
Int. coverage 77.58x
Stability
16 /100
Unstable Beta 1.50x
EPS volatility 439.92%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CRMD
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Joseph Todisco
Employees
191
Headquarters
Parsippany
Upcoming events
11 NOV
Earnings
Upcoming earnings report